Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-23 20:01 | 2026-06-22 | MLTX | MoonLake Immunotherapeutics | Bodenstedt Matthias | Officer | SELL | $22.04 | 39,120 | $862,205 | 1,115,435 |
| 2026-06-23 20:01 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | Brumm Joshua T | Director, Officer | SELL | $17.99 | 42,305 | $761,067 | 281,212 |
| 2026-06-23 20:02 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | McNeill Jonathan | Officer | SELL | $17.99 | 20,549 | $369,677 | 139,158 |
| 2026-06-23 20:02 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | Im Ellie Eunkyung | Officer | SELL | $17.99 | 1,219 | $21,930 | 22,069 |
| 2026-06-23 20:03 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | Bispham Barbara Harlin | Officer | SELL | $17.99 | 1,218 | $21,912 | 19,330 |
| 2026-06-23 20:03 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | Scalzo Richard William | Officer | SELL | $17.99 | 1,112 | $20,005 | 20,298 |
| 2026-06-23 20:04 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | Pinkas Jan | Officer | SELL | $17.99 | 1,288 | $23,171 | 22,239 |
| 2026-06-23 20:04 | 2026-06-22 | CBIO | CRESCENT BIOPHARMA, INC. | Lynch Ryan | Officer | SELL | $17.99 | 465 | $8,365 | 13,871 |
| 2026-06-22 20:05 | 2026-06-18 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Director, Officer | SELL | $2.71 | 1,776 | $4,813 | 390,247 |
| 2026-06-23 00:18 | 2026-06-22 | SVRA | Savara Inc | Lowrance David L | Officer | OPT+S | $5.68 | 394,528 | $2,241,432 | 536,032 |
| 2026-06-22 23:59 | 2026-06-22 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | Officer | SELL | $80.95 | 1,587 | $128,468 | 15,312 |
| 2026-06-22 23:15 | 2026-05-22 | SER | Serina Therapeutics, Inc. | Venkatesan Jay | Director | BUY | $1.78 | 589 | $1,048 | 589 |
| 2026-06-22 22:59 | 2026-06-17 | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | SELL | $0.35 | 416,911 | $145,919 | 303,719 |
| 2026-06-22 22:00 | 2026-06-18 | KURA | Kura Oncology, Inc. | Leoni Mollie | Officer | SELL | $9.82 | 84,929 | $834,283 | 182,345 |
| 2026-06-22 21:20 | 2026-06-17 | PTCT | PTC THERAPEUTICS, INC. | Utter Christine Marie | Officer | OPT+S | $75.56 | 19,686 | $1,487,474 | 70,199 |
| 2026-06-22 21:23 | 2026-06-18 | NBP | NovaBridge Biosciences | Dennis Phillip Andrew | Officer | OPT+S | $0.66 | 8,494 | $5,606 | 157,941 |
| 2026-06-22 21:06 | 2026-06-17 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer | OPT+S | $110.73 | 4,302 | $476,373 | 0 |
| 2026-06-22 21:11 | 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $43.80 | 5,000 | $219,017 | 25,000 |
| 2026-06-22 21:13 | 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $43.80 | 6,018 | $263,578 | 51,000 |
| 2026-06-22 21:20 | 2026-06-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $78.65 | 10,462 | $822,868 | 105,272 |
| 2026-06-22 20:30 | 2026-06-22 | OTLC | Oncotelic Therapeutics, Inc. | Shah Amit B. | Officer | BUY | $0.05 | 20,000 | $1,000 | 378,837 |
| 2026-06-22 20:30 | 2026-06-18 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $540.18 | 9,500 | $5,131,711 | 40,513 |
| 2026-06-22 20:31 | 2026-06-18 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $540.15 | 10,000 | $5,401,488 | 18,876 |
| 2026-06-22 20:15 | 2026-06-17 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Director | SELL | $20.10 | 84,355 | $1,695,687 | 4,112,218 |
| 2026-06-22 20:00 | 2026-06-18 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew | Officer | SELL | $32.19 | 9,989 | $321,547 | 0 |
| 2026-06-22 20:01 | 2026-06-18 | XNCR | Xencor Inc | Feigal Ellen | Director | SELL | $13.06 | 6,843 | $89,370 | 12,340 |
| 2026-06-22 20:01 | 2026-06-18 | ARDX | ARDELYX, INC. | Williams Laura A | Officer | OPT+S | $5.99 | 81,898 | $490,487 | 378,195 |
| 2026-06-22 20:02 | 2026-06-09 | GYRE | GYRE THERAPEUTICS, INC. | Ye Weiguo | Officer | OPT+S | $6.25 | 11,000 | $68,701 | 700,000 |
| 2026-06-22 14:30 | 2026-06-17 | KTTA | Pasithea Therapeutics Corp. | Coastlands Capital LP | 10% owner | BUY | $0.53 | 100,000 | $53,000 | 3,835,035 |
| 2026-06-22 12:31 | 2026-06-17 | QURE | uniQure N.V. | Kapusta Matthew C | Director, Officer | OPT+S | $45.47 | 206,100 | $9,371,614 | 521,795 |
| 2026-06-22 12:05 | 2026-06-17 | QURE | uniQure N.V. | Balachandran Madhavan | Director | OPT+S | $45.06 | 11,685 | $526,484 | 43,254 |
| 2026-06-22 11:54 | 2026-06-17 | QURE | uniQure N.V. | Kaye Jack | Director | OPT+S | $42.57 | 5,295 | $225,408 | 25,996 |
| 2026-06-22 11:12 | 2026-06-17 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer | BUY | $3.10 | 6,550 | $20,305 | 163,541 |
| 2026-06-22 10:05 | 2026-06-18 | BLTE | BELITE BIO, INC | Scholl Hendrik Peter | Officer | SELL | $145.24 | 10,000 | $1,452,435 | 15,000 |
| 2026-06-18 20:30 | 2026-06-17 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Veness Adam M | Officer | OPT+S | $80.80 | 30,000 | $2,423,958 | 0 |
| 2026-06-18 20:06 | 2026-06-17 | ARVN | ARVINAS, INC. | Cacace Angela M | Officer | SELL | $7.60 | 2,576 | $19,565 | 180,390 |
| 2026-06-18 21:05 | 2026-06-16 | CMND | Clearmind Medicine Inc. | HRT FINANCIAL LP | 10% owner | SELL | $3.31 | 22,139 | $73,192 | 81,353 |
| 2026-06-18 20:06 | 2026-06-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $3.16 | 11,824 | $37,305 | 667,524 |
| 2026-06-18 20:06 | 2026-06-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Director, Officer | SELL | $3.16 | 53,588 | $169,070 | 2,119,111 |
| 2026-06-18 20:05 | 2026-06-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $3.16 | 10,773 | $33,989 | 702,829 |
| 2026-06-18 23:08 | 2026-06-16 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $60.75 | 20,000 | $1,215,056 | 55,045 |
| 2026-06-18 22:36 | 2026-06-16 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $3.18 | 4,126 | $13,110 | 128,589 |
| 2026-06-18 22:39 | 2026-06-17 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | SELL | $101.95 | 2,594 | $264,458 | 5,835 |
| 2026-06-18 22:45 | 2026-06-17 | MLTX | MoonLake Immunotherapeutics | Bodenstedt Matthias | Officer | SELL | $19.67 | 17,876 | $351,576 | 1,154,555 |
| 2026-06-18 21:23 | 2026-06-17 | CRNX | Crinetics Pharmaceuticals, Inc. | Okey Stephanie | Director | SELL | $35.67 | 6,900 | $246,143 | 6,400 |
| 2026-06-18 21:08 | 2026-05-07 | ABT | ABBOTT LABORATORIES | Stratton John G | Director | BUY | $86.82 | 2,000 | $173,640 | 23,319 |
| 2026-06-18 21:14 | 2026-06-16 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $0.01 | 3,132,480 | $40,722 | 0 |
| 2026-06-18 21:19 | 2026-06-16 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $265.39 | 1,169 | $310,236 | 0 |
| 2026-06-18 21:19 | 2026-06-16 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | SELL | $265.98 | 590 | $156,925 | 0 |
| 2026-06-18 21:19 | 2026-06-16 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $265.55 | 3,693 | $980,686 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.